About this item:

152 Views | 256 Downloads

Author Notes:

Paul E. Holtzheimer, MD, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Northeast, Suite 4000, Atlanta, GA 30322, USA. pholtzh@emory.edu.

Authors' disclosures available in full text.

Subjects:

Research Funding:

This work was supported by National Institutes of Health/National Institute of Mental Health grants MH-58922, MH-42088, MH-69056 and MH-77083 (to Dr. Nemeroff); and MH-77869 (to Dr. Holtzheimer); the National Institutes of Health Loan Repayment Program (Dr. Holtzheimer); and NARSAD (Dr. Holtzheimer).

Keywords:

  • Antidepressive Agents
  • Antipsychotic Agents
  • Biogenic Monoamines
  • Brain
  • Deep Brain Stimulation
  • Depressive Disorder, Major
  • Drug Therapy, Combination
  • Drugs, Investigational
  • Electroconvulsive Therapy
  • Humans
  • Receptors, Neurotransmitter
  • Transcranial Magnetic Stimulation
  • Vagus Nerve Stimulation

Novel targets for antidepressant therapies

Tools:

Journal Title:

Current Psychiatry Reports

Volume:

Volume 10, Number 6

Publisher:

, Pages 465-473

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Most depressed patients fail to achieve remission despite adequate antidepressant monotherapy, and a substantial minority show minimal improvement despite optimal and aggressive therapy. However, major advances have taken place in elucidating the neurobiology of depression, and several novel targets for antidepressant therapy have emerged. Three primary approaches are currently being taken: 1) optimizing the pharmacologic modulation of monoaminergic neurotransmission, 2) developing medications that target neurotransmitter systems other than the monoamines, and 3) directly modulating neuronal activity via focal brain stimulation. We review novel therapeutic targets for developing improved antidepressant therapies, including triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, dopamine receptor agonists, corticotropin-releasing factor-1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists,N-methyl-d-aspartate receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy, transcranial direct current stimulation, and deep brain stimulation.

Copyright information:

© Current Medicine Group LLC 2008.

Export to EndNote